Trial of Quetiapine in Anorexia Nervosa

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Anorexia Nervosa
Interventions
DRUG

Quetiapine

Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.

DRUG

Placebo

Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.

Trial Locations (1)

92037

UCSD Department of Psychiatry Center for Eating Disorder Research, San Diego

All Listed Sponsors
collaborator

University of South Florida

OTHER

lead

University of California, San Diego

OTHER

NCT00518973 - Trial of Quetiapine in Anorexia Nervosa | Biotech Hunter | Biotech Hunter